Award Data

Accurate Automation Corporation will develop a carbon nanotube based microstrip plasma limiter suitable for inclusion on RF printed circuit boards used on the front-end of an X-Band phased-array receiver. This device will capitalize on the ability to use carbon nanotubes to reduce the size and cost of an RF limiter while dramatically increasing the performance. Specific attention will be focused o ...

This STTR Phase I proposal proposes to design and develop reactive filter media using nanofiber technology to capture corrosion inducing particulate matter present in coastal region air. The fibrous filter media will be functionalized using ion exchange chemistry which is known to react with salt ions. The media will be characterized for its filtration performance, resistance to airflow, and dus ...

? DESCRIPTION (provided by applicant): The goal of this Phase I STTR project is to establish the feasibility of developing a small-molecule therapeutic agent designed to prevent rhabdomyolysis-induced renal failure. Rhabdomyolysis accounts for 7% to 10% of cases of renal failure in the US. Rhabdomyolysis results from muscle injury that leads to the release of myoglobin, which is then deposited ...

DESCRIPTION (provided by applicant): Currently, FDA approved clinical applications of 9-Tetrahydrocannabinol (THC) include control of nausea and vomiting associated with chemotherapy and for appetite stimulation for AIDS patients suffering from anorexia and wasting syndrome. However, THC also has significant potential in the treatment of glaucoma, the second largest cause of blindness, by dec ...

DESCRIPTION (provided by applicant): The overall goal of our work is to establish the potency and efficacy of a novel 2-adrenergic receptor agonist (compound 49b) in the prevention and/or reversal of non-proliferative diabetic retinopathy. Diabetic retinopathy is the leading cause of blindness in working age adults. The current treatment paradigm for retinopathy patients has not changed signif ...

DESCRIPTION (provided by applicant): There is an urgent, unmet need for novel therapeutic approaches that are efficacious against lung cancer. Ranking first among cancer deaths in the U.S., this disease has 5-year relative survival rates of lt20%. Most lung cancers are non-small cell (NSCLC, 85% of cases). Curative surgery is not an option for the 80% of NSCLC patients who present with advanced s ...